Lanean...
Dasatinib promotes TRAIL‐mediated apoptosis by upregulating CHOP‐dependent death receptor 5 in gastric cancer
Dasatinib, a tyrosine kinase inhibitor, has been approved for first‐line treatment of leukemia and has also been evaluated for use in numerous other cancers. However, its role in gastric cancer (GC) remains unclear. Therefore, the aim of this study was to investigate how dasatinib suppresses the gro...
Gorde:
| Argitaratua izan da: | FEBS Open Bio |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley and Sons Inc.
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5929929/ https://ncbi.nlm.nih.gov/pubmed/29744288 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/2211-5463.12404 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|